{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:28:45Z","timestamp":1784838525210,"version":"3.55.0"},"reference-count":191,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.prp.2025.155954","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:41:12Z","timestamp":1744188072000},"page":"155954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance"],"prefix":"10.1016","volume":"270","author":[{"given":"Kumarappan","family":"Chidambaram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rekha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsas","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.prp.2025.155954_bib1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1158\/1055-9965.EPI-19-0221","article-title":"Cancer progress and priorities: lung cancer","volume":"28","author":"Schabath","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ddr.21895","article-title":"Races of small molecule clinical trials for the treatment of COVID-19: an up-to-date comprehensive review","volume":"83","author":"Hu","year":"2022","journal-title":"Drug Dev. Res."},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041375","article-title":"Understanding breast cancer aggressiveness and its implications in diagnosis and treatment","volume":"12","author":"Afifi","year":"2023","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.prp.2025.155954_bib4","article-title":"MALAT1: a key regulator in lung cancer pathogenesis and therapeutic targeting","author":"Bhat","year":"2023","journal-title":"Pathol. -Res. Pract."},{"issue":"12","key":"10.1016\/j.prp.2025.155954_bib5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","article-title":"Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"19","author":"Ganti","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib6","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/1759-7714.13141","article-title":"Tobacco smoking and trends in histological subtypes of female lung cancer at the Cancer Hospital of the Chinese Academy of Medical Sciences over 13\u2009years","volume":"10","author":"Zeng","year":"2019","journal-title":"Thorac. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2025.155954_bib7","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3390\/pharmaceutics14122788","article-title":"Polysaccharide-based nanomedicines targeting lung cancer","volume":"14","author":"Bhat","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2025.155954_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115891","article-title":"Advances and challenges in the treatment of lung cancer","volume":"169","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2025.155954_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cancergen.2024.04.001","article-title":"CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer","volume":"284","author":"Li","year":"2024","journal-title":"Cancer Genet."},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.bbamcr.2007.01.012","article-title":"Ras oncogenes and their downstream targets","volume":"1773","author":"Rajalingam","year":"2007","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways in the regulation of cell proliferation in mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res."},{"issue":"14","key":"10.1016\/j.prp.2025.155954_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells11142183","article-title":"Crucial role of oncogenic KRAS mutations in apoptosis and autophagy regulation: therapeutic implications","volume":"11","author":"Ferreira","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.prp.2025.155954_bib14","doi-asserted-by":"crossref","first-page":"1321576","DOI":"10.3389\/fendo.2023.1321576","article-title":"Endocrine and metabolic factors and the risk of idiopathic pulmonary fibrosis: a Mendelian randomization study","volume":"14","author":"Jiang","year":"2024","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.prp.2025.155954_bib15","article-title":"Genomic landscape of lung adenocarcinomas in different races","volume":"12","author":"Shi","year":"2022","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5732\/cjc.012.10098","article-title":"The genetics and biology of KRAS in lung cancer","volume":"32","author":"Westcott","year":"2013","journal-title":"Chin. J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/cbr.2015.1921","article-title":"Regulation of oncoprotein 18\/stathmin signaling by ERK concerns the resistance to taxol in nonsmall cell lung cancer cells","volume":"31","author":"Lin","year":"2016","journal-title":"Cancer Biotherapy Radiopharm."},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/JTO.0000000000000432","article-title":"Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas","volume":"10","author":"Yu","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2025.155954_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071586","article-title":"The role of tumor microenvironment in chemoresistance: to survive, keep your enemies closer","volume":"18","author":"Senthebane","year":"2017","journal-title":"Int J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.prp.2025.155954_bib20","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/onc.2015.375","article-title":"Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma","volume":"35","author":"Schabath","year":"2016","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib21","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/jpp\/rgae058","article-title":"The mechanism of action of Botrychium (Thunb.) Sw. for prevention of idiopathic pulmonary fibrosis based on 1H NMR-based metabolomics","volume":"76","author":"Lou","year":"2024","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","article-title":"Targeting KRAS mutant cancers: from druggable therapy to drug resistance","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1574362409666140206221931","article-title":"Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops","volume":"8","author":"von Manstein","year":"2013","journal-title":"Curr. Signal Transduct. Ther."},{"key":"10.1016\/j.prp.2025.155954_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115937","article-title":"Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS\/MS and its application in the clinical determination in patients with tumors associated with overactive bladder","volume":"240","author":"Lou","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"41","key":"10.1016\/j.prp.2025.155954_bib25","doi-asserted-by":"crossref","first-page":"eade3816","DOI":"10.1126\/sciadv.ade3816","article-title":"Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer","volume":"9","author":"Mohanty","year":"2023","journal-title":"Sci. Adv."},{"issue":"19","key":"10.1016\/j.prp.2025.155954_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194562","article-title":"Current landscape of therapeutic resistance in lung cancer and promising strategies to overcome resistance","volume":"14","author":"Ashrafi","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ymthe.2022.11.011","article-title":"PROTAC therapy as a new targeted therapy for lung cancer","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13062-024-00497-8","article-title":"Ubiquitin recruiting chimera: more than just a PROTAC","volume":"19","author":"Grigoreva","year":"2024","journal-title":"Biol. Direct"},{"key":"10.1016\/j.prp.2025.155954_bib31","doi-asserted-by":"crossref","first-page":"1432869","DOI":"10.3389\/fonc.2024.1432869","article-title":"Evaluation of a three-gene methylation model for correlating lymph node metastasis in postoperative early gastric cancer adjacent samples","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2025.155954_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110446","article-title":"The mechanism of action and clinical value of PROTACs: a graphical review","volume":"99","author":"Graham","year":"2022","journal-title":"Cell. Signal."},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib33","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.prp.2025.155954_bib34","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.semcancer.2015.03.001","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35","author":"Mohammad","year":"2015","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib35","doi-asserted-by":"crossref","first-page":"25331","DOI":"10.1038\/s41598-024-76798-9","article-title":"Comprehensive pan-cancer analysis reveals ENC1 as a promising prognostic biomarker for tumor microenvironment and therapeutic responses","volume":"14","author":"Cao","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2025.155954_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113392","article-title":"Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies","volume":"144","author":"Sun","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib38","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/2159-8290.CD-22-0035","article-title":"Classification of KRAS-Activating Mutations and the Implications for therapeutic intervention","volume":"12","author":"Johnson","year":"2022","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib39","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Weinberg, Hallmarks of Cancer: The Next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.prp.2025.155954_bib40","first-page":"15","article-title":"Drugging the undruggable: Ross Cagan interviews Kevan Shokat","author":"Cagan","year":"2022","journal-title":"Dis. Models Mech."},{"issue":"15","key":"10.1016\/j.prp.2025.155954_bib41","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1039\/D1OB00356A","article-title":"Discovery of a highly efficient nitroaryl group for detection of nitroreductase and imaging of hypoxic tumor cells","volume":"19","author":"Wang","year":"2021","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41698-021-00237-5","article-title":"Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes","volume":"5","author":"Palma","year":"2021","journal-title":"npj Precis. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib43","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.18632\/oncotarget.23553","article-title":"Implications of KRAS mutations in acquired resistance to treatment in NSCLC","volume":"9","author":"Del Re","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.21037\/tlcr-22-639","article-title":"Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review","volume":"12","author":"Santarpia","year":"2023","journal-title":"Transl. Lung Cancer Res"},{"issue":"294","key":"10.1016\/j.prp.2025.155954_bib45","doi-asserted-by":"crossref","first-page":"re6","DOI":"10.1126\/scisignal.2004652","article-title":"Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer","volume":"6","author":"Niederst","year":"2013","journal-title":"Sci. Signal"},{"key":"10.1016\/j.prp.2025.155954_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/150960","article-title":"Clinical relevance of KRAS in human cancers","volume":"2010","author":"Janc\u00edk","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4618","article-title":"Functional analysis of protein post-translational modifications using genetic codon expansion","volume":"32","author":"Peng","year":"2023","journal-title":"Protein Sci."},{"issue":"9","key":"10.1016\/j.prp.2025.155954_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092934","article-title":"Targeting PI3K\/Akt\/mTOR in AML: rationale and clinical Evidence","volume":"9","author":"Darici","year":"2020","journal-title":"J. Clin. Med"},{"issue":"6","key":"10.1016\/j.prp.2025.155954_bib49","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-022-00454-5","article-title":"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer","volume":"22","author":"Labrie","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10522-025-10208-z","article-title":"Hypoxia-inducible factor and cellular senescence in pulmonary aging and disease","volume":"26","author":"Thapa","year":"2025","journal-title":"Biogerontology"},{"issue":"13","key":"10.1016\/j.prp.2025.155954_bib51","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.7150\/thno.71260","article-title":"Conquering oncogenic KRAS and its bypass mechanisms","volume":"12","author":"Hou","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib52","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cell.2020.09.044","article-title":"Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients","volume":"183","author":"Kim","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK Pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib54","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","article-title":"Targeting KRAS mutant cancers: from druggable therapy to drug resistance","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2025.155954_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119983","article-title":"Exosomal ncRNAs in liquid biopsies for lung cancer","volume":"565","author":"Sadique Hussain","year":"2025","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib56","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.18632\/oncotarget.13907","article-title":"The role of tumor microenvironment in therapeutic resistance","volume":"8","author":"Son","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2025.155954_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864739","article-title":"Dual relationship between stromal cells and immune cells in the tumor microenvironment","volume":"13","author":"Mun","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib58","first-page":"129","article-title":"Resistance to immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer","volume":"5","author":"Li","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.prp.2025.155954_bib59","doi-asserted-by":"crossref","DOI":"10.2174\/0115680096360059250131075456","article-title":"Groundbreaking mRNA lung cancer vaccine trials: a new dawn in cancer treatment","author":"Hussain","year":"2025","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.prp.2025.155954_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164413","article-title":"Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas","volume":"133","author":"Salm\u00f3n","year":"2023","journal-title":"J. Clin. Invest"},{"issue":"22","key":"10.1016\/j.prp.2025.155954_bib61","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1158\/0008-5472.CAN-21-1606","article-title":"Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies","volume":"81","author":"Wajapeyee","year":"2021","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.prp.2025.155954_bib62","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1161\/CIRCULATIONAHA.110.956839","article-title":"Epigenetic modifications: basic mechanisms and role in cardiovascular disease","volume":"123","author":"Handy","year":"2011","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.prp.2025.155954_bib63","article-title":"Influence of gut and lung dysbiosis on lung cancer progression and their modulation as promising therapeutic targets: a comprehensive review","volume":"5","author":"Thapa","year":"2024","journal-title":"MedComm (2020)"},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib64","doi-asserted-by":"crossref","first-page":"508","DOI":"10.5732\/cjc.011.10267","article-title":"Metabolic alterations in cancer cells and therapeutic implications","volume":"30","author":"Hammoudi","year":"2011","journal-title":"Chin. J. Cancer"},{"issue":"13","key":"10.1016\/j.prp.2025.155954_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133210","article-title":"Epigenetic deregulation of apoptosis in cancers","volume":"13","author":"Ozyerli-Goknar","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.prp.2025.155954_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112541","article-title":"KRAS G12C Mutations in NSCLC: from target to resistance","volume":"13","author":"Addeo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2025.155954_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102576","article-title":"Epithelial-mesenchymal transition to mitigate age-related progression in lung cancer","volume":"102","author":"Thapa","year":"2024","journal-title":"Ageing Res Rev."},{"issue":"24","key":"10.1016\/j.prp.2025.155954_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27248828","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy: present and future","volume":"27","author":"Li","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.prp.2025.155954_bib69","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138920310791824057","article-title":"The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention","volume":"11","author":"Chen","year":"2010","journal-title":"Curr. Protein Pept. Sci."},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib70","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.70009","article-title":"CRBN-PROTACs in cancer therapy: from mechanistic insights to clinical applications","volume":"104","author":"Thapa","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib71","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.prp.2025.155954_bib72","article-title":"Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer","volume":"256","author":"Singh","year":"2024","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2025.155954_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.692574","article-title":"PROTAC: an effective targeted protein degradation strategy for cancer therapy","volume":"12","author":"Qi","year":"2021","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s11658-016-0031-z","article-title":"p62 links the autophagy pathway and the ubiqutin\u2013proteasome system upon ubiquitinated protein degradation","volume":"21","author":"Liu","year":"2016","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.prp.2025.155954_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116275","article-title":"Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer","volume":"173","author":"Lee","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.prp.2025.155954_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.685106","article-title":"Opportunities and challenges of small molecule induced targeted protein degradation","volume":"9","author":"He","year":"2021","journal-title":"Front Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib77","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/acs.biochem.2c00366","article-title":"Targeting scaffolding functions of enzymes using PROTAC approaches","volume":"62","author":"Kim","year":"2023","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.prp.2025.155954_bib78","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"26","key":"10.1016\/j.prp.2025.155954_bib79","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","article-title":"PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics","volume":"39","author":"Khan","year":"2020","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.prp.2025.155954_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38409","article-title":"Liposomal encapsulated curcumin attenuates lung cancer proliferation, migration, and induces apoptosis","volume":"10","author":"Kokkinis","year":"2024","journal-title":"Heliyon"},{"issue":"11","key":"10.1016\/j.prp.2025.155954_bib81","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41589-020-00652-y","article-title":"PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase","volume":"16","author":"Adhikari","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.prp.2025.155954_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.crchbi.2022.100020","article-title":"Expanding the landscape of E3 ligases for targeted protein degradation","volume":"2","author":"Kramer","year":"2022","journal-title":"Curr. Res. Chem. Biol."},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib83","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/17460441.2021.1915979","article-title":"Is PROTAC technology really a game changer for central nervous system drug discovery?","volume":"16","author":"Farrell","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"issue":"13","key":"10.1016\/j.prp.2025.155954_bib84","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103395","article-title":"PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery","volume":"28","author":"Guedeney","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"21","key":"10.1016\/j.prp.2025.155954_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215430","article-title":"KRAS in NSCLC: state of the art and future perspectives","volume":"14","author":"Cascetta","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib87","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.gendis.2021.08.011","article-title":"Covalent inhibitor targets KRasG12C: a new paradigm for drugging the undruggable and challenges ahead","volume":"10","author":"Li","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.prp.2025.155954_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102315","article-title":"Cellular senescence in lung cancer: molecular mechanisms and therapeutic interventions","volume":"97","author":"Jha","year":"2024","journal-title":"Ageing Res Rev."},{"issue":"11","key":"10.1016\/j.prp.2025.155954_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111615","article-title":"Origin of antibiotics and antibiotic resistance, and their impacts on drug development: a narrative review","volume":"16","author":"Muteeb","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.prp.2025.155954_bib90","article-title":"Treatment strategies for KRAS-mutated non-small-cell lung cancer","volume":"15","author":"O'Sullivan","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib91","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","article-title":"Focal adhesion kinase: from biological functions to therapeutic strategies","volume":"12","author":"Tan","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112868","article-title":"FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer","volume":"408","author":"Liu","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.prp.2025.155954_bib93","article-title":"PVT1 lncRNA in lung cancer: a key player in tumorigenesis and therapeutic opportunities","volume":"253","author":"Hakami","year":"2024","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.prp.2025.155954_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113116","article-title":"Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment","volume":"151","author":"Wu","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.prp.2025.155954_bib95","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1083\/jcb.200912094","article-title":"Role of kinase-independent and -dependent functions of FAK in endothelial cell survival and barrier function during embryonic development","volume":"189","author":"Zhao","year":"2010","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.prp.2025.155954_bib96","article-title":"Harnessing pyroptosis for lung cancer therapy: the impact of NLRP3 inflammasome activation","volume":"260","author":"Dahiya","year":"2024","journal-title":"Pathol. Res Pr."},{"issue":"10","key":"10.1016\/j.prp.2025.155954_bib97","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib98","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22241","article-title":"Targeted degradation of KRAS protein in non-small cell lung cancer: therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles","volume":"85","author":"Wang","year":"2024","journal-title":"Drug Dev. Res."},{"issue":"22","key":"10.1016\/j.prp.2025.155954_bib99","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225599","article-title":"Oncogenic KRAS: signaling and drug resistance","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib101","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.prp.2025.155954_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114088","article-title":"Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC","volume":"230","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib103","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRAS(G12C) by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib104","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib105","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6_ement","key":"10.1016\/j.prp.2025.155954_bib106","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1158\/1538-7445.AM2024-6513","article-title":"Abstract 6513: discovery and characterization of a KRASG12C\/D\/V degrader with potent anti-tumor activity in KRASmut-driven preclinical models","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib107","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/acsmedchemlett.3c00111","article-title":"Targeted degradation of KRASG12D as potential therapy in cancer","volume":"14","author":"Kargbo","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib108","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1517\/14712590902735795","article-title":"Mechanisms of tumor resistance to EGFR-targeted therapies","volume":"13","author":"Hopper-Borge","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.prp.2025.155954_bib109","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","article-title":"Mechanisms of resistance to KRAS(G12C)-targeted therapy","volume":"11","author":"Akhave","year":"2021","journal-title":"Cancer Discov."},{"issue":"13","key":"10.1016\/j.prp.2025.155954_bib110","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/1759-7714.14858","article-title":"Precision targeted therapy for EGFR mutation-positive NSCLC: Dilemmas and coping strategies","volume":"14","author":"Meng","year":"2023","journal-title":"Thorac. Cancer"},{"issue":"9","key":"10.1016\/j.prp.2025.155954_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/cells8091013","article-title":"Highlights in resistance mechanism pathways for combination therapy","volume":"8","author":"Delou","year":"2019","journal-title":"Cells"},{"issue":"23","key":"10.1016\/j.prp.2025.155954_bib112","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.prp.2025.155954_bib113","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.155954_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front Oncol."},{"issue":"17","key":"10.1016\/j.prp.2025.155954_bib115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.161820","article-title":"Targeting BCL-XL in fibrolamellar hepatocellular carcinoma","volume":"7","author":"Shebl","year":"2022","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.prp.2025.155954_bib116","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202100689","article-title":"Strategies to reduce the on-target platelet toxicity of Bcl-xL inhibitors: PROTACs, SNIPERs and prodrug-based approaches","volume":"23","author":"Negi","year":"2022","journal-title":"ChemBioChem"},{"issue":"10","key":"10.1016\/j.prp.2025.155954_bib117","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","article-title":"Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"108","author":"Jia","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib118","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1158\/1535-7163.MCT-22-0301","article-title":"Bcl-xL is a key mediator of apoptosis following KRASG12C inhibition in KRASG12C-mutant colorectal cancer","volume":"22","author":"Khawaja","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib119","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-022-01241-3","article-title":"BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers","volume":"15","author":"Khan","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"20","key":"10.1016\/j.prp.2025.155954_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205059","article-title":"Progress on Ras\/MAPK signaling research and targeting in blood and solid cancers","volume":"13","author":"Dillon","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib121","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib122","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1021\/acs.jmedchem.3c01598","article-title":"A potent SOS1 PROTAC degrader with synergistic efficacy in combination with KRASG12C inhibitor","volume":"67","author":"Lv","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.prp.2025.155954_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010151","article-title":"Mechanisms of resistance to KRAS(G12C) inhibitors","volume":"13","author":"Dunnett-Kane","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib125","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.2337\/diabetes.51.8.2420","article-title":"The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism","volume":"51","author":"Hawley","year":"2002","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib126","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.3390\/ijms24054331","article-title":"A novel combination of sotorasib and metformin enhances cytotoxicity and apoptosis in KRAS-mutated non-small cell lung cancer cell lines through MAPK and P70S6K Inhibition","volume":"24","author":"Barrios-Bernal","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib127","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/1878-0261.12831","article-title":"SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis","volume":"15","author":"Liu","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.prp.2025.155954_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217282","article-title":"SMARCA4 and SMARCA2 co-deficiency: an uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodeling","volume":"605","author":"Field","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2025.155954_bib129","first-page":"2024","article-title":"Discovery of novel, potent and orally bioavailable SMARCA2 PROTACs with synergistic anti-tumor activity in combination with KRAS G12C inhibitors","author":"Kotagiri","year":"2024","journal-title":"bioRxiv"},{"issue":"44","key":"10.1016\/j.prp.2025.155954_bib130","doi-asserted-by":"crossref","first-page":"eadl6464","DOI":"10.1126\/sciadv.adl6464","article-title":"Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor\u2013induced immune responses","volume":"10","author":"Cole","year":"2024","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib131","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.21037\/tlcr.2018.03.19","article-title":"Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer","volume":"7","author":"Gregorc","year":"2018","journal-title":"Transl. Lung Cancer Res"},{"issue":"9","key":"10.1016\/j.prp.2025.155954_bib132","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.prp.2025.155954_bib133","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ccell.2023.07.005","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer","volume":"41","author":"de Miguel","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib134","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","article-title":"Combine and conquer: challenges for targeted therapy combinations in early phase trials","volume":"14","author":"Lopez","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.155954_bib135","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential impact of the multi-target drug approach in the treatment of some complex diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Develop Ther."},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib136","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17460441.2023.2187777","article-title":"Novel approaches to targeted protein degradation technologies in drug discovery","volume":"18","author":"Xue","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib137","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib138","article-title":"Targeted protein degradation in cancers: orthodox PROTACs and beyond","volume":"4","author":"Li","year":"2023","journal-title":"Innovation"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib139","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41598-021-81262-z","article-title":"Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody","volume":"11","author":"Tanaka","year":"2021","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.prp.2025.155954_bib140","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00018-019-03112-6","article-title":"Advances in targeted degradation of endogenous proteins","volume":"76","author":"R\u00f6th","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib141","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1038\/s41467-020-17022-w","article-title":"A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS","volume":"11","author":"Bery","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.prp.2025.155954_bib142","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1158\/1078-0432.CCR-19-4060","article-title":"Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting","volume":"26","author":"Yaeger","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.prp.2025.155954_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115857","article-title":"Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation","volume":"261","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib144","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12672-022-00550-w","article-title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines","volume":"13","author":"Plangger","year":"2022","journal-title":"Discov. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib145","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.37349\/etat.2023.00178","article-title":"Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer","volume":"4","author":"Hamilton","year":"2023","journal-title":"Explor Target Antitumor Ther."},{"issue":"7","key":"10.1016\/j.prp.2025.155954_bib146","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib147","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.prp.2025.155954_bib148","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14225546","article-title":"Cell-penetrating peptides (CPPs) as therapeutic and diagnostic agents for cancer","volume":"14","author":"Bottens","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib149","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5114\/bta.2021.108724","article-title":"Nanoantibodies: small molecules, big possibilities","volume":"102","author":"Pedre\u00e1\u00f1ez","year":"2021","journal-title":"Biotechnol. (Pozn. )"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41421-024-00699-4","article-title":"A pan-KRAS degrader for the treatment of KRAS-mutant cancers","volume":"10","author":"Yang","year":"2024","journal-title":"Cell Discov."},{"issue":"40","key":"10.1016\/j.prp.2025.155954_bib151","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1200\/EDBK_280845","article-title":"Strategic combinations to prevent and overcome resistance to targeted therapies in oncology","author":"Gumusay","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"19","key":"10.1016\/j.prp.2025.155954_bib152","article-title":"Current molecular combination therapies used for the treatment of breast cancer","volume":"23","author":"Wang","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib153","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3390\/ijms16011928","article-title":"BRD4 inhibitor inhibits colorectal cancer growth and metastasis","volume":"16","author":"Hu","year":"2015","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2025.155954_bib154","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.2147\/OTT.S100515","article-title":"BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects","volume":"9","author":"Abedin","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"9","key":"10.1016\/j.prp.2025.155954_bib155","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","article-title":"Understanding resistance to EGFR inhibitors-impact on future treatment strategies","volume":"7","author":"Wheeler","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.prp.2025.155954_bib156","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jconrel.2024.10.007","article-title":"Targeted nanoliposomes of oncogenic protein degraders: significant inhibition of tumor in lung-cancer bearing mice","volume":"376","author":"Vartak","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2025.155954_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216065","article-title":"PROTACs: promising approach for anticancer therapy","volume":"556","author":"Kaur","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib158","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","article-title":"BRD4 and cancer: going beyond transcriptional regulation","volume":"17","author":"Donati","year":"2018","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2025.155954_bib159","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41419-022-05505-1","article-title":"Regulation of programmed cell death by Brd4","volume":"13","author":"Hu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.prp.2025.155954_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106793","article-title":"Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors","volume":"140","author":"Fan","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"13","key":"10.1016\/j.prp.2025.155954_bib161","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med Chem."},{"issue":"4","key":"10.1016\/j.prp.2025.155954_bib162","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging All KRAS mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib163","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","article-title":"Drugging KRAS: current perspectives and state-of-art review","volume":"15","author":"Parikh","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib164","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.gendis.2021.08.011","article-title":"Covalent inhibitor targets KRas(G12C): a new paradigm for drugging the undruggable and challenges ahead","volume":"10","author":"Li","year":"2023","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"issue":"22","key":"10.1016\/j.prp.2025.155954_bib166","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216346","article-title":"PROTAC-based protein degradation as a promising strategy for targeted therapy in sarcomas","volume":"24","author":"Mancarella","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.prp.2025.155954_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26247561","article-title":"Recent developments in targeting RAS downstream effectors for RAS-driven cancer therapy","volume":"26","author":"Tatli","year":"2021","journal-title":"Molecules"},{"issue":"23","key":"10.1016\/j.prp.2025.155954_bib168","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315440","article-title":"Targeted protein degradation: clinical advances in the field of oncology","volume":"23","author":"Salama","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.prp.2025.155954_bib169","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.prp.2025.155954_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24183308","article-title":"Structural insights into the regulation mechanism of small GTPases by GEFs","volume":"24","author":"Toma-Fukai","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib171","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BCJ20220234","article-title":"Dynamic regulation of RAS and RAS signaling","volume":"480","author":"Kolch","year":"2023","journal-title":"Biochem J."},{"key":"10.1016\/j.prp.2025.155954_bib172","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.semcancer.2015.02.006","article-title":"Sustained proliferation in cancer: mechanisms and novel therapeutic targets","volume":"35","author":"Feitelson","year":"2015","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.prp.2025.155954_bib173","doi-asserted-by":"crossref","first-page":"672","DOI":"10.18632\/oncotarget.28469","article-title":"Targeting ras with protein engineering","volume":"14","author":"Tomazini","year":"2023","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib174","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","article-title":"Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.prp.2025.155954_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115408","article-title":"Targeted protein degradation for the treatment of Parkinson\u2019s disease: advances and future perspective","volume":"166","author":"Amirian","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.prp.2025.155954_bib176","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.chembiol.2020.06.012","article-title":"Targeting endogenous K-RAS for degradation through the affinity-directed protein missile system","volume":"27","author":"R\u00f6th","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"5","key":"10.1016\/j.prp.2025.155954_bib177","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","author":"Nabet","year":"2018","journal-title":"Nat. Chem. Biol."},{"issue":"9","key":"10.1016\/j.prp.2025.155954_bib178","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.chembiol.2020.06.012","article-title":"Targeting endogenous K-RAS for degradation through the affinity-directed protein missile system","volume":"27","author":"R\u00f6th","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib179","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010198","article-title":"Targeting aberrant RAS\/RAF\/MEK\/ERK signaling for cancer therapy","volume":"9","author":"Degirmenci","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.prp.2025.155954_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.118570","article-title":"Therapeutic targeting of RAS: new hope for drugging the undruggable","volume":"1867","author":"Khan","year":"2020","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Cell Res."},{"issue":"5_ement","key":"10.1016\/j.prp.2025.155954_bib181","doi-asserted-by":"crossref","first-page":"B039","DOI":"10.1158\/1557-3125.RAS23-B039","article-title":"Abstract B039: BIO-PROTAC: application of cell penetrating scFv to treat undruggable KRAS mutant cancer","volume":"21","author":"Yoon","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.prp.2025.155954_bib182","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.prp.2025.155954_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.prp.2025.155954_bib184","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/14728222.2021.1902991","article-title":"KRAS G12C inhibition and innate immune targeting","volume":"25","author":"Tani","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.prp.2025.155954_bib185","article-title":"Transcriptomic mapping of non-small cell lung cancer K-RAS p.G12C mutated tumors: identification of surfaceome targets and immunologic correlates","volume":"12","author":"Alcaraz-Sanabria","year":"2021","journal-title":"Front Immunol."},{"issue":"14","key":"10.1016\/j.prp.2025.155954_bib186","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1074\/jbc.REV118.002958","article-title":"Evolution of the multi-tRNA synthetase complex and its role in cancer","volume":"294","author":"Hyeon","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.prp.2025.155954_bib187","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41419-020-02794-2","article-title":"Roles of aminoacyl-tRNA synthetase-interacting multi-functional proteins in physiology and cancer","volume":"11","author":"Zhou","year":"2020","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.prp.2025.155954_bib188","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5483\/BMBRep.2024-0053","article-title":"Identification and structure of AIMP2-DX2 for therapeutic perspectives","volume":"57","author":"Kim","year":"2024","journal-title":"BMB Rep."},{"key":"10.1016\/j.prp.2025.155954_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2024.08.004","article-title":"Chemical induction of the interaction between AIMP2-DX2 and Siah1 to enhance ubiquitination","author":"Kim","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"13","key":"10.1016\/j.prp.2025.155954_bib190","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1021\/jm3017706","article-title":"Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators","volume":"56","author":"Wang","year":"2013","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.prp.2025.155954_bib191","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14756366.2022.2135510","article-title":"Synthesis and discovery of the first potent proteolysis targeting chimaera (PROTAC) degrader of AIMP2-DX2 as a lung cancer drug","volume":"38","author":"Lee","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033825001463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T14:34:45Z","timestamp":1747406085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033825001463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":191,"alternative-id":["S0344033825001463"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2025.155954","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting KRAS-G12C in lung cancer: The emerging role of PROTACs in overcoming resistance","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2025.155954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155954"}}